Gulf Pharmaceutical
Gulf Pharmaceutical Industries, commonly known as Julphar, is a leading pharmaceutical company headquartered in the United Arab Emirates (AE). Established in 1980, Julphar has grown to become a prominent player in the Middle East and North Africa (MENA) region, focusing on the development, manufacturing, and distribution of high-quality pharmaceutical products. With a diverse portfolio that includes prescription medications, over-the-counter products, and biotechnology solutions, Julphar is renowned for its commitment to innovation and quality. The company has achieved significant milestones, including the establishment of state-of-the-art manufacturing facilities and a robust research and development programme. Julphar's dedication to excellence has positioned it as a trusted name in the pharmaceutical industry, contributing to improved healthcare outcomes across its operational regions.
DitchCarbon Score
How does Gulf Pharmaceutical's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Medical Device Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Gulf Pharmaceutical's score of 5 is higher than 55% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Gulf Pharmaceutical's reported carbon emissions
In 2023, Gulf Pharmaceutical reported total carbon emissions of approximately 35,100 kg CO2e, comprising about 6,300 kg CO2e from Scope 1 and about 29,400 kg CO2e from Scope 2 emissions. This marks a slight decrease from 2022, where emissions were about 35,800 kg CO2e. Over the years, the company has shown a trend of reducing its emissions, with a notable drop from about 66,810,000 kg CO2e in 2019 to the current figures. Despite these reductions, Gulf Pharmaceutical has not publicly committed to specific reduction targets or initiatives, as indicated by the absence of documented reduction targets or climate pledges. The company continues to focus on managing its Scope 1 and Scope 2 emissions, which are critical for its overall carbon footprint. As Gulf Pharmaceutical operates within the pharmaceutical industry, it is essential for the company to align its practices with global climate standards and expectations, particularly in light of increasing scrutiny on corporate sustainability efforts.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
Add to project| 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | |
|---|---|---|---|---|---|---|---|
| Scope 1 | 8,417,000 | 0,000,000 | 0,000,000 | 0,000 | 0,000 | 0,000 | 0,000 |
| Scope 2 | 33,350,000 | 00,000,000 | 00,000,000 | 00,000 | 00,000 | 00,000 | 00,000 |
| Scope 3 | - | - | - | - | - | - | - |
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Gulf Pharmaceutical is not committed to any reduction initiatives we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
